Phase II randomized trial of carboplatin + pemetrexed + bevacizumab, +/- atezolizumab in stage IV non-squamous non-small lung cancer (NSCLC) patients who harbor a sensitizing EGFR mutation or have never smoked.

Authors

null

Joseph Nicholas Bodor

Fox Chase Cancer Center, Philadelphia, PA

Joseph Nicholas Bodor , Jyoti D. Patel , Eric A. Ross , Samuel Litwin , Margie Clapper , Benjamin Philip Levy , Heather A. Wakelee , Hossein Borghaei , Joseph Treat

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03786692

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS9629)

DOI

10.1200/JCO.2020.38.15_suppl.TPS9629

Abstract #

TPS9629

Poster Bd #

395

Abstract Disclosures